NRIX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

13.41M

+0.98%

-0.922

+22.98%

16.72M

-9.4%

-0.834

+24.52%

17.50M

-60.28%

-0.841

+61.81%

Estimates Revision

The market is revising Downward the revenue expectations for Nurix Therapeutics, Inc. (NRIX) for FY2025, with the revenue forecasts being adjusted by -2.34% over the past three months. During the same period, the stock price has changed by 97.75%.

Revenue Estimates for FY2025

Revise Downward

-2.34%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.41%

In Past 3 Month

Stock Price

Go Up

+97.75%

In Past 3 Month

15 Analyst Rating

Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 24.93 USD with a low forecast of 12.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

12.00

Averages

24.93

High

33.00

Current: 0.000

Low

12.00

Averages

24.93

High

33.00

Morgan Stanley

Equal Weight -> Overweight

upgrade

$15 -> $36

2026-01-08

New

Reason

Morgan Stanley

Price Target

$15 -> $36

2026-01-08

New

upgrade

Equal Weight -> Overweight

Reason

Morgan Stanley upgraded Nurix Therapeutics to Overweight from Equal Weight with a price target of $36, up from $15. The firm sees a higher probability of success for bexobrutideg and chronic lymphocytic leukemia. In addition, Nurix has "building pipeline optionality" with STAT6 and IRAK4 degraders entering the clinic, the analyst tells investors in a research note.

Mizuho

Outperform

maintain

$24 -> $30

2025-12-10

Reason

Mizuho

Price Target

$24 -> $30

2025-12-10

maintain

Outperform

Reason

Mizuho raised the firm's price target on Nurix Therapeutics (NRIX) to $30 from $24 and keeps an Outperform rating on the shares. The key opinion leader with which the firm hosted a call at the ASH meeting believes Nurix's bexobrutideg is shaping up to have a more favorable profile than BeOne Medicines' (ONC) BGB-16673, reports the analyst.

H.C. Wainwright

Robert Burns

Buy

maintain

$28 -> $31

2025-12-10

Reason

H.C. Wainwright

Robert Burns

Price Target

$28 -> $31

2025-12-10

maintain

Buy

Reason

H.C. Wainwright analyst Robert Burns raised the firm's price target on Nurix Therapeutics to $31 from $28 and keeps a Buy rating on the shares. The firm says the updated data for bexobrutideg potentially de-risks the confirmatory trial.

BTIG

Buy

maintain

$27 -> $30

2025-12-09

Reason

BTIG

Price Target

$27 -> $30

2025-12-09

maintain

Buy

Reason

BTIG raised the firm's price target on Nurix Therapeutics to $30 from $27 and keeps a Buy rating on the shares. The company hosted a webcast to discuss updated Phase 1a/1b data for BTK degrader bexobrutideg in r/r chronic lymphocytic leukemia patients presented at ASH this weekend, and aside from compelling mPFS of 22.1 months and mDOR of 20.1 months in phase 1a, and dose dependent Objective Response Rate observed in the 600mg phase 1b cohort, the firm comes away noting how encouraged key opinion leader Dr. Alencar was on bexdeg's "remarkable" tolerability and efficacy, the analyst tells investors in a research note.

Truist

NULL -> Buy

initiated

$23 -> $30

2025-11-24

Reason

Truist

Price Target

$23 -> $30

2025-11-24

initiated

NULL -> Buy

Reason

Truist assumed coverage of Nurix Therapeutics with a Buy rating with a price target of $30, up from $23. The firm sees the company's bexo's clinical data and pivotal trial start in CLL - chronic lymphocytic leukemia - as a meaningful proof-of-concept for Nurix's protein degradation platform, the analyst tells investors in a research note. Truist adds that the combination of a de-risked lead program in hem-onc and the broad optionality and catalyst path in I&I - inflammation and immunology - are the central pillars of its investment thesis for the stock.

JPMorgan

Tessa Romero

Overweight

downgrade

$30 -> $22

2025-11-18

Reason

JPMorgan

Tessa Romero

Price Target

$30 -> $22

2025-11-18

downgrade

Overweight

Reason

JPMorgan analyst Tessa Romero lowered the firm's price target on Nurix Therapeutics to $22 from $30 and keeps an Overweight rating on the shares following a transfer of coverage. The firm views Nurix as a "differentiated name" within the emerging oral target protein degrader space.

Valuation Metrics

The current forward P/E ratio for Nurix Therapeutics Inc (NRIX.O) is -5.19, compared to its 5-year average forward P/E of -5.73. For a more detailed relative valuation and DCF analysis to assess Nurix Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.73

Current PE

-5.19

Overvalued PE

-2.31

Undervalued PE

-9.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.49

Current EV/EBITDA

-4.85

Overvalued EV/EBITDA

-0.58

Undervalued EV/EBITDA

-6.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

17.82

Current PS

29.03

Overvalued PS

29.06

Undervalued PS

6.58

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 418.49% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 418.49% over the last month.

Sold

Bought

NRIX News & Events

Events Timeline

No data

News

6.0

01-08CNBC

Evercore ISI Upgrades Roku to Outperform, Raises Price Target to $145

2.0

2025-12-24Globenewswire

GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing

2.0

2025-12-08Benzinga

Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More

People Also Watch

Frequently Asked Questions

What is Nurix Therapeutics Inc (NRIX) stock price today?

The current price of NRIX is 19.3 USD — it has increased 3.6 % in the last trading day.

What is Nurix Therapeutics Inc (NRIX)'s business?

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.

What is the price predicton of NRIX Stock?

What is Nurix Therapeutics Inc (NRIX)'s revenue for the last quarter?

Nurix Therapeutics Inc revenue for the last quarter amounts to 7.89M USD, decreased -37.29 % YoY.

What is Nurix Therapeutics Inc (NRIX)'s earnings per share (EPS) for the last quarter?

Nurix Therapeutics Inc. EPS for the last quarter amounts to -1.03 USD, increased 53.73 % YoY.

What changes have occurred in the market's expectations for Nurix Therapeutics Inc (NRIX)'s fundamentals?

How many employees does Nurix Therapeutics Inc (NRIX). have?

Nurix Therapeutics Inc (NRIX) has 286 emplpoyees as of January 10 2026.

What is Nurix Therapeutics Inc (NRIX) market cap?

Today NRIX has the market capitalization of 1.96B USD.